Minimally invasive procedures play a crucial role in the management of pelvic congestion syndrome (PCS) by offering effective treatment options with reduced recovery times and lower complication rates compared to traditional surgeries. One of the primary procedures used is pelvic vein embolization, where a catheter is inserted into the affected veins under imaging guidance. Through this procedure, embolic agents are delivered to block off varicose veins, relieving symptoms such as pelvic pain and discomfort. This approach addresses the underlying cause of PCS and promotes quicker recovery and minimal scarring, making it a preferred choice for many patients seeking long-term relief from PCS symptoms.
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) and Dihydroergotamine), Application (Primary Pelvic Congestion Syndrome and Secondary Pelvic Congestion Syndrome) – Industry Trends and Forecast to 2031
.
The Global Pelvic Congestion Syndrome Market size was valued at USD 680.13 USD Million in 2023.
The Global Pelvic Congestion Syndrome Market is projected to grow at a CAGR of 6.56% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa.
